论文部分内容阅读
由上海第十三制药厂生产的一种治疗病毒性肝炎的新药——门冬氨酸钾镁注射液,于1984年3月在上海通过鉴定。门冬氨酸钾镁注射液是一种含钾、镁两种离子的L型氨基酸(L-门冬氨酸)制剂,具有增强各种细胞的活力、加速肝细胞内三羧酸循环、改善肝功能的作用。临床适用于改善心肌细胞功能(如心肌炎后遗症、心肌病、早搏等),也可用于某些肝病(如肝硬化、非溶血性高胆红素血症等)。 1981～1982年,上海第二医学院附属瑞金医院、第九人民医院根据门冬氨酸钾镁的药理作用,结合病毒性肝炎高胆红素血症的发病机制,将该注射液用于治疗各型病毒性肝炎的高胆红素血症,获得满意效果。后又经上海市门冬氨酸钾镁治疗肝炎协作组(瑞金医院等共11所医院),采用双盲法进行了临床研究,并对225例研究对象
A new drug for the treatment of viral hepatitis produced by Shanghai No. 13 Pharmaceutical Factory, potassium-magnesium aspartate injection, was approved in Shanghai in March 1984. Aspartate potassium magnesium injection is a potassium, magnesium ions of L-type amino acid (L-aspartic acid) preparation, with various cells to enhance the vitality and accelerate the intracellular tricarboxylic acid cycle, improve The role of liver function. Clinical application of cardiomyocytes to improve myocardial function (such as myocarditis sequelae, cardiomyopathy, premature beats, etc.), can also be used for some liver diseases (such as cirrhosis, non-hemolytic hyperbilirubinemia, etc.). From 1981 to 1982, the Second Affiliated Hospital of Shanghai Ruijin Hospital, the Ninth People’s Hospital based on the pharmacological effects of potassium aspartate magnesium, combined with the pathogenesis of viral hepatitis hyperbilirubinemia, the injection for the treatment Various types of viral hepatitis hyperbilirubinemia, access to satisfactory results. After Shanghai aspartate potassium and magnesium treatment of hepatitis co-operation group (Ruijin Hospital and a total of 11 hospitals), a double-blind clinical study carried out, and 225 cases of subjects